And even though LJPC is closer to market, using the same indication (anti-galectin) for a similarly huge potential indication (CKD instead of NASH), here we sit at about even with a marekt cap about 1/10th of GALTs.
IF the phase 2 data are good, this will play catch up in a hurry, and in a big big way.
Market Data 
Markets 
